Share: Facebook Twitter LinkedIn
Activity Provided By:

Physicians’ Education Resource®, LLC.

New Targets, New Combinations, New Treatment Goals: Assessing Therapeutic Options to Personalize Care in Multiple Myeloma

Access Activity

Overview / Abstract:

Target Audience

The target audience for this activity is hematologists and oncologists who treat patients with MM. Physicians, nurses, and other health care professionals interested in the treatment of MM are also invited to participate.

Activity Overview

Almost all patients with multiple myeloma (MM) eventually relapse with the disease course typically involving multiple relapses and remissions. Therapy selection for relapsed or refractory (R/R) MM is nuanced and affected by many variables. This along with the availability of novel therapies and accumulating evidence can make it difficult for clinicians to select appropriate therapy for individual patients. This accredited program discusses patient cases, applicable data, and management strategies in order to facilitate care for patients across the MM disease continuum.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Translate patient-specific factors, risk stratification, and treatment history into personalized treatment plans for patients with R/R MM
Assess recent results from pivotal trials on current and emerging therapeutic approaches for the treatment of R/R MM
Implement effective strategies to monitor and mitigate the negative impact of treatment-related toxicities in patients with R/R MM
Apply recent guidelines in parallel with practice-changing evidence on evolving single agent and combination approaches to real-world case scenarios typically encountered in R/R MM management


Dec 23, 2022



Credits / Hours

2.0 AMA PRA Category 1 Credit(s)™



Presenters / Authors / Faculty


Ajai Chari, MD (Chair)
Professor of Medicine, Hematology, and Medical Oncology
Icahn School of Medicine at Mount Sinai
Director of Clinical Research, Multiple Myeloma Program
Mount Sinai Health System
New York, NY

Sikander Ailawadhi, MD
Professor of Medicine
Lead, International Cancer Center
Division of Hematology/Oncology
Department of Medicine
Mayo Clinic
Jacksonville, FL

Nizar Jacques Bahlis, MD
Associate Professor
Hematology and Bone Marrow Transplantation
Cumming School of Medicine, University of Calgary
Member, Arnie Charbonneau Cancer Institute
Calgary, AB, Canada

Neha S. Korde, MD
Associate Professor
Memorial Sloan Kettering Cancer Center
New York, NY

Cesar Rodriguez Valdes, MD
Associate Professor of Medicine
Hematology and Medical Oncology
Clinical Director, Multiple Myeloma
The Mount Sinai Hospital
New York, NY

Sponsors / Supporters / Grant Providers

Amgen, Inc., Karyopharm Therapeutics, Legend Biotech USA, Inc., Oncopeptides, Sanofi Genzyme, Secura Bio, Inc., and Takeda Oncology.

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., Multiple Myeloma Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map